Sirio Pharma
Sirio Pharma Co., Ltd. operates as a contract manufacturer for dietary supplement industry worldwide. The company develops and manufactures a range of softgel dietary supplements; vegetarian softgel; nutritious gummies; probiotic balls; tablet and powder products; capsules; and functional beverages. It also offers a range of services, including primary and final packaging. Sirio Pharma Co., Ltd. … Read more
Sirio Pharma (300791) - Total Liabilities
Latest total liabilities as of June 2025: CN¥3.07 Billion CNY
Based on the latest financial reports, Sirio Pharma (300791) has total liabilities worth CN¥3.07 Billion CNY as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Sirio Pharma - Total Liabilities Trend (2016–2024)
This chart illustrates how Sirio Pharma's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Sirio Pharma Competitors by Total Liabilities
The table below lists competitors of Sirio Pharma ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
First Bank
NASDAQ:FRBA
|
USA | $3.51 Billion |
|
Beijing Century Real Tech
SHE:300150
|
China | CN¥432.18 Million |
|
Beijing Yuanlong Yato Culture Dissemination Co Ltd
SHE:002878
|
China | CN¥823.79 Million |
|
Luxfer Holdings PLC
NYSE:LXFR
|
USA | $145.80 Million |
|
Yuanta Futures Co Ltd
TWO:6023
|
Taiwan | NT$177.56 Billion |
|
Suzhou Kelida Bldg &
SHG:603828
|
China | CN¥3.37 Billion |
|
Anhui Ankai Automobile Co Ltd
SHE:000868
|
China | CN¥3.37 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down Sirio Pharma's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.93 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.54 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sirio Pharma's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sirio Pharma (2016–2024)
The table below shows the annual total liabilities of Sirio Pharma from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥2.84 Billion | +8.19% |
| 2023-12-31 | CN¥2.63 Billion | +77.16% |
| 2022-12-31 | CN¥1.48 Billion | +16.38% |
| 2021-12-31 | CN¥1.28 Billion | +173.12% |
| 2020-12-31 | CN¥466.95 Million | +12.79% |
| 2019-12-31 | CN¥414.01 Million | -45.49% |
| 2018-12-31 | CN¥759.53 Million | +7.34% |
| 2017-12-31 | CN¥707.58 Million | -29.03% |
| 2016-12-31 | CN¥997.00 Million | -- |